Results 161 to 170 of about 16,969,588 (288)

Combined P-Value Functions for Compatible Effect Estimation and Hypothesis Testing in Drug Regulation. [PDF]

Stat Med
Pawel S, Roos M, Held L.
europepmc   +1 more source

The P value - and its historical underpinnings - pro and con. [PDF]

Saudi J Anaesth, 2023
Grech V, Eldawlatly AA.
europepmc   +1 more source

Local Lipschitz continuity in the initial value and strong completeness for nonlinear stochastic differential equations

Recently, Hairer et. al (2012) showed that there exist SDEs with infinitely often differentiable and globally bounded coefficient functions whose solutions fail to be locally Lipschitz continuous in the strong L^p-sense with respect to the initial value ...
Cox, Sonja, Hutzenthaler, Martin, Jentzen, Arnulf   +2 more
core  

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

The <i>P</i> Value: What It Is and What It Is Not. [PDF]

J Korean Med Sci
Habibzadeh F.
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Decision Rules in Frequentist and Bayesian Hypothesis Testing: P-Value and Bayes Factor. [PDF]

Int J Public Health
Fordellone M, Schiattarella P, Nicolao G, Signoriello S, Chiodini P.   +4 more
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

On the effect of flexible adjustment of the p value significance threshold on the reproducibility of randomized clinical trials. [PDF]

PLoS One
Habibzadeh F.
europepmc   +1 more source

Interpreting Results from Statistical Hypothesis Testing: Understanding the Appropriate P-value. [PDF]

Phys Ther Res, 2022
Tsushima E.
europepmc   +1 more source